Research at the Clayton Foundation has led to several FDA approved drugs, medical devices and diagnostic assays along with the following pipeline in development by our licensees.
Clinical Pipeline
LentiGlobin
Indication: Sickle Cell Disease
Phase II / III
Oral Vimo-001
Indication: Solid Tumors
Phase I
Pre-Clinical Pipeline
Dengue Virus Vaccine
Indication: 4 serotype dengue vaccine
IND in preparation
Chikungunya Virus Vaccine
Indication: vaccine to chikungunya
IND enabling studies
Zika Virus Vaccine
Indication: vaccine to zika
IND enabling studies
RT-200
Indication: Type II Diabetes
Advanced Preclinical
RT-300
Indication: Congestive Heart Failure
Preclinical
RT-400
Indication: Acute decompensated heart failure
Preclinical
GrB-Fc-SD1
Indication: Mesotheliomas & Pancreatic Cancers
Preclinical
GrB-Fc-IT4
Indication: Breast and other solid tumors
Preclinical
GrB-Fc-VEGF
Indication: Wet AMD & Choroidal Neovascularization
Preclinical
Early Stage Pipeline
JamC mAb
Indication: B Cell Lymphomas
Animal in vivo POC
Olfml3 mAb
Indication: Metastatic breast cancer
Animal in vivo POC
HI P. Goldsteinii
Indication: Osteoporosis and Obesity
Preclinical
HDAC inhibitors for TB
Valproic acid to treat TB
Drug repurposing